AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
June 25, 2019NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
-
June 24, 2019- FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria
-
June 20, 2019
-
June 12, 2019- Data from SELECT-EARLY and SELECT-COMPARE show a significantly higher proportion of patients treated with upadacitinib monotherapy or in combination with methotrexate (MTX) maintaining clinical remission compared with MTX or adalimumab plus MTX, respectively, at 48 weeks1,2
-
June 11, 2019- Longer-term results from IMMhance showed 73 percent and 72 percent of patients treated with continuous SKYRIZI™ (risankizumab) experienced complete skin clearance (defined as sPGA 0 and PASI 100, respectively) at week 94, among patients who achieved sPGA 0/1 at week 28 [1]
-
May 30, 2019- AbbVie to present more than 40 abstracts from its oncology pipeline at this year's ASCO and EHA medical meetings in June
-
May 17, 2019-Phase 3 INTELLANCE-1 study, conducted in collaboration with the RTOG Foundation, did not meet primary endpoint of overall survival at the interim analysis and demonstrated no survival benefit for patients receiving Depatux-M
-
May 15, 2019- FDA reviewed the submission under the Real-Time Oncology Review pilot program
-
April 30, 2019- Approval based on results from clinical studies showing high rates of skin clearance at 16 weeks; this clearance was durable at one year with every 12-week dosing[1-4]
-
April 30, 2019- Presentations include updates on ABBV-951, a subcutaneous infusion therapy for Parkinson's disease (PD), and elezanumab, a monoclonal antibody directed against repulsive guidance molecule A (RGMa) in multiple sclerosis (MS), among other data to be presented
-
April 25, 2019- Reports First-Quarter Diluted EPS of $1.65 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 14.4 Percent
-
April 23, 2019- Approval based on clinical trials showing people treated with SKYRIZI™ (risankizumab-rzaa) every 12 weeks - four doses a year after two initial doses - achieved high levels of durable skin clearance at 16 weeks and maintained this response at one year[1-3]
-
April 03, 2019
-
March 26, 2019-This marks the first regulatory approval globally for SKYRIZI™ (risankizumab)
-
March 07, 2019- The Phase 3 CLL14 trial of venetoclax in combination with obinutuzumab is the first randomized clinical trial to examine a chemotherapy-free treatment given for a fixed duration in previously-untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities
-
March 01, 2019- CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission(1-3)
-
February 28, 2019
-
February 25, 2019- Nineteen abstracts underscore AbbVie's continued pursuit of research on behalf of patients living with chronic dermatologic conditions
-
February 22, 2019- Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein
-
February 21, 2019
-
February 19, 2019- Upadacitinib, an investigational once-daily oral JAK1-selective inhibitor, is being studied for the treatment of adult patients with moderate to severe rheumatoid arthritis[1-8]
-
January 28, 2019- Milestone marks the 10th FDA approval for IMBRUVICA in six different disease areas since 2013
-
January 25, 2019- Reports Full-Year Diluted EPS of $3.66 on a GAAP Basis; Adjusted Diluted EPS of $7.91 Reflects Growth of 41.3 Percent
-
January 18, 2019-- The RESOLVE (PCYC-1137) trial evaluated ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents
-
January 03, 2019- Initiation of clinical studies with TTX-030 is targeted in Q1 2019
-
December 20, 2018- Regulatory applications supported by robust SELECT Phase 3 program evaluating more than 4,000 patients with moderate to severe rheumatoid arthritis[1-5]
-
December 20, 2018
-
December 17, 2018
-
December 13, 2018
-
December 05, 2018- Independent Data Monitoring Committee responsible for ongoing review of study data recommended enrollment be stopped
-
December 04, 2018- Results from this interim analysis showed ibrutinib plus rituximab prolonged progression-free survival (PFS) compared to a standard chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) at nearly 3 years of follow-up (abstract #LBA-4)
-
December 03, 2018- These data were included in the recent sNDA accepted by the U.S. FDA, which received Priority Review, and could lead to the first chemotherapy-free anti-CD20 combination approved for first-line CLL treatment
-
December 02, 2018- With up to seven years of treatment, sustained PFS rates with ibrutinib in CLL/small lymphocytic lymphoma (SLL) at 80 percent for previously untreated patients
-
December 01, 2018- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up[1]
-
November 30, 2018
-
November 21, 2018- Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for patients who are ineligible for intensive chemotherapy[1,2]
-
November 20, 2018- AbbVie will present nearly 40 abstracts featuring data from approved and investigational medicines
-
November 14, 2018-Elagolix, in combination with add-back therapy, achieved statistically significant reduction in heavy menstrual bleeding associated with uterine fibroids compared to placebo
-
November 13, 2018- EXPEDITION-8 is the first Phase 3b study evaluating 8 weeks of MAVYRET™ in treatment-naïve chronic hepatitis C virus (HCV)-infected patients with compensated cirrhosis across all major genotypes (GT1-6)[1]
-
November 13, 2018
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
